Innovating Works

SWEATPATCH

Financiado
Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Response
Breast Cancer (BC) is the most common cancer in Europe. In most cases, BC will present at a locally advanced or distant stage, which requiresanticancer drugs. However, there is no guarantee that the favorable drug benefit/risk bal... Breast Cancer (BC) is the most common cancer in Europe. In most cases, BC will present at a locally advanced or distant stage, which requiresanticancer drugs. However, there is no guarantee that the favorable drug benefit/risk balance will align with expectations at an individual level or be maintained over time. Therefore, monitoring tumor response to treatment is critical for timely adjusting the therapeutic strategy to improve patients’ outcomes. To fulfill this unmet medical need,SWEATPATCH proposesan innovative non- invasive approach to monitor in real-time BC response to treatment, based on emerging odorous biomarkers, namely volatile organic compounds (VOCs) from sweat emanated from the breast skin. Due to their connection to breast tumor metabolism, sweat VOCs are promising candidate biomarkers for monitoring tumor response to treatment.SWEATPATCH breakthrough relies on a radically-new technology with cutting-edge straintronic microwave based on phononic metamaterials and nanomaterials chemtronics technologies to solve scientific bottlenecks for sweat VOCs analysis in the near field of cancer cells.SWEATPATCH will gather an interdisciplinary consortium of leading experts in materials, sensors, data processing, and translational/clinical oncology, from 6 countries. The consortium will develop a groundbreaking wireless Lab-on-a-Patch to (1) monitor BC therapeutic response directly from the breast surface using a novel biocompatible flexible patch combined with specific data analysis that (2) will also be adaptable to in vitro 3D culture systems of patients’ derived organoids, a tumor model avatar created from patients’ BC, which will be used for drug screening to modelize tumor response to treatment.SWEATPATCH will convey a considerable conceptual leap that will shift the current healthcare paradigm from «one-size-fit-all» monitoring to «a smart real-time personalized monitoring»synchronized to tumor biology to reach precision oncology. ver más
31/03/2028
CENTRALE LILLE INS...
3M€
Duración del proyecto: 48 meses Fecha Inicio: 2024-03-12
Fecha Fin: 2028-03-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-12
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-PATHFINDEROPEN-01-01: EIC Pathfinder Open
Cerrada hace 1 año
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
CENTRALE LILLE INSTITUT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5